Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...
BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder. The company said it is exploring ...
of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.
The 36th International Pharmaceutical Exhibition “CPhI Worldwide – CPhI Frankfurt 2025” has opened in Frankfurt, Germany.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback